|
HMGN2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.52410000970372E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.62060000033593E-07 |
| Normal-vs-Stage2 |
9.044100E-04 |
| Normal-vs-Stage3 |
1.13950000546481E-08 |
| Normal-vs-Stage4 |
1.83850000001762E-07 |
| Stage1-vs-Stage2 |
7.295800E-01 |
| Stage1-vs-Stage3 |
1.099410E-01 |
| Stage1-vs-Stage4 |
8.462300E-02 |
| Stage2-vs-Stage3 |
5.544800E-01 |
| Stage2-vs-Stage4 |
3.693400E-01 |
| Stage3-vs-Stage4 |
6.290200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.70099994884532E-09 |
| Normal-vs-AfricanAmerican |
1.020830E-01 |
| Normal-vs-Asian |
5.365300E-04 |
| Caucasian-vs-AfricanAmerican |
3.761200E-01 |
| Caucasian-vs-Asian |
3.189000E-01 |
| AfricanAmerican-vs-Asian |
7.560600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.23809999999602E-06 |
| Normal-vs-Female |
6.91089996340821E-09 |
| Male-vs-Female |
5.846600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.28839999999453E-05 |
| Normal-vs-Age(41-60Yrs) |
1.40100000489696E-08 |
| Normal-vs-Age(61-80Yrs) |
4.86079999584277E-08 |
| Normal-vs-Age(81-100Yrs) |
7.025000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.113570E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.013800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.415200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.027200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.694400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.434800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.400030E-04 |
| Classical-VS-Follicular |
9.018200E-01 |
| Classical-VS-Other |
8.331800E-01 |
| Classical-VS-Normal |
1.89139999995369E-06 |
| Tall-VS-Follicular |
7.859000E-03 |
| Tall-VS-Other |
9.203700E-02 |
| Tall-VS-Normal |
1.36890054847072E-10 |
| Follicular-VS-Other |
8.561600E-01 |
| Follicular-VS-Normal |
2.835700E-04 |
| Other-VS-Normal |
1.665600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.15349999996184E-06 |
| Normal-vs-N1 |
1.53410000036658E-07 |
| N0-vs-N1 |
1.386600E-01 |
|
|
